Carl Feinstein

Carl Feinstein

Auto-generated profile, based on publicly available information

Carl Feinstein

Departments of Pediatrics, Biomedical Data Science, Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, United States

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Schizophrenia Research
Verified
Journal Article
Closed access
Martin DebbanéMartin Debbané
Martin Debbané
BGBronwyn Glaser
Bronwyn Glaser
MDMelissa K. David
Melissa K. David
CFCarl Feinstein
Carl Feinstein
SEStephan Eliez
Stephan Eliez

22 April 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ANAnish Nag
Anish Nag
NHNick Haber
Nick Haber
CVCatalin Voss
Catalin Voss
STSerena Tamura
Serena Tamura
JDJena Daniels
Jena Daniels
DWDennis Wall
Dennis Wall
Background: Several studies have shown that facial attention differs in children with autism. Measuring eye gaze and emotion recognition in children with autism is challenging, as standard clinical assessments must be delivered in clinical settings by a trained clinician. Wearable technologies may be able to bring eye gaze and emotion recognition into natural social interactions and settings. Objective: This study aimed to test: (1) the feasibility of tracking gaze using wearable smart glasses during a facial expression recognition task and (2) the ability of these gaze-tracking data, together with facial expression recognition responses, to distinguish children with autism from neurotypical controls (NCs). Methods: We compared the eye gaze and emotion recognition patterns of 16 children with autism spectrum disorder (ASD) and 17 children without ASD via wearable smart glasses fitted with a custom eye tracker. Children identified static facial expressions of images presented on a computer screen along with nonsocial distractors while wearing Google Glass and the eye tracker. Faces were presented in three trials, during one of which children received feedback in the form of the correct classification. We employed hybrid human-labeling and computer vision–enabled methods for pupil tracking and world–gaze translation calibration. We analyzed the impact of gaze and emotion recognition features in a prediction task aiming to distinguish children with ASD from NC participants. Results: Gaze and emotion recognition patterns enabled the training of a classifier that distinguished ASD and NC groups. However, it was unable to significantly outperform other classifiers that used only age and gender features, suggesting that further work is necessary to disentangle these effects. Conclusions: Although wearable smart glasses show promise in identifying subtle differences in gaze tracking and emotion recognition patterns in children with and without ASD, the present form factor and data do not allow for these differences to be reliably exploited by machine learning systems. Resolving these challenges will be an important step toward continuous tracking of the ASD phenotype.

1 July 2007 in Child and Adolescent Psychiatric Clinics of North America
Verified
Journal Article
Closed access
CFCarl Feinstein
Carl Feinstein
SSSonia Singh
Sonia Singh

1 October 2017 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
JDJena Daniels
Jena Daniels
JSJessey Schwartz
Jessey Schwartz
NHNick Haber
Nick Haber
CVCatalin Voss
Catalin Voss
AKAaron Kline
Aaron Kline
DWDennis Wall
Dennis Wall

1 September 2000 in Current Opinion in Psychiatry
Verified
Journal Article
Closed access
CFCarl Feinstein
Carl Feinstein
SEStephan Eliez
Stephan Eliez
Velocardiofacial syndrome (VCFS) is a genetic disability syndrome that is caused, in most cases, by a de-novo 3 Mb microdeletion at chromosome region 22q11.2. The behavioral phenotype includes characteristic developmental, cognitive, and linguistic deficits, and psychiatric disorders, including childhood abnormalities of attention, mood, and anxiety. Recently, it was established that approximately 30% of people with VCFS develop schizophrenia, establishing VCFS as the first known genetic cause of schizophrenia. There has been recent progress in describing the molecular biology of the deletion site, characterizing the behavioral phenotype, and in defining the structural brain abnormalities in VCFS. However, numerous knowledge gaps remain in tracing the pathways from gene expression to brain structure, and to cognitive and psychiatric symptoms.

1 November 2009 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
CFCarl Feinstein
Carl Feinstein